New Campaign Aims to Inspire People With Psoriasis to Show More of Their True Selves
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160817005604/en/
Fresh off her poolside reporting assignment in Rio, Torres is speaking
out about her personal experience with psoriasis. The Olympic swimmer
and author was diagnosed with plaque psoriasis in the late 1990s. As one
of 7.5 million people in the
"I started noticing red, irritable, flaky patches on my elbows and back that seemed to be aggravated by stress, but I didn't let fear or embarrassment keep me out of a bathing suit or out of the pool," said Torres. "Instead, I worked with my dermatologist to manage my plaque psoriasis symptoms and didn't let the impact of the disease force me to adapt my life at the expense of my dreams. I want to encourage others to do the same."
People living with psoriasis often report that the disease has emotional and physical challenges. In fact, a survey reported nearly 9 out of 10 people living with psoriasis experienced self-consciousness or embarrassment about their condition. This survey also showed about half of patients with psoriasis are dissatisfied with their treatment options.
Otezla is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Please see Important Safety Information for Otezla below.
"My psoriasis patients not only deal with the physical symptoms of their
disease, but because it is visible to the world, it can also affect how
they see themselves and how they perceive others see them," said
"Celgene believes that people living with psoriasis should not only have
different treatment options available, but should also have support to
help them better understand their disease," said
To learn more about the SHOW MORE OF YOU campaign, psoriasis, Torres' personal story, and to upload inspiring photos or messages, visit www.ShowMoreOfYou.com.
Psoriasis is a chronic skin condition affecting approximately 7.5
million people in
Otezla® (apremilast) treats plaque psoriasis differently. Otezla is a pill - not an injection, not a cream, and not a biologic. For more information, talk to your dermatologist or visit www.otezla.com.
Otezla is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
IMPORTANT SAFETY INFORMATION
You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.
Otezla is associated with an increase in adverse reactions of depression. In clinical studies, some patients reported depression and suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, suicidal thoughts, or suicidal behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.
Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla.
Some medicines may make Otezla® (apremilast) less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.
Side effects of Otezla were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache.
These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.
Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed. Otezla has not been studied in pregnant women or in women who are breastfeeding.
You are encouraged to report negative side effects of prescription drugs
Visit www.fda.gov/medwatch, or call 1-800-332-1088.
Please click here for Full Prescribing Information.
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made.
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
Senior Director, Corporate Communications
News Provided by Acquire Media